Regenxbio Inc (NASDAQ:RGNX) insider Kenneth T. Mills sold 15,000 shares of the company’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $42.99, for a total value of $644,850.00. Following the completion of the sale, the insider now owns 261,000 shares of the company’s stock, valued at approximately $11,220,390. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Regenxbio stock opened at $45.64 on Friday. Regenxbio Inc has a 1 year low of $38.56 and a 1 year high of $85.10. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of 19.18 and a beta of 0.37. The company has a quick ratio of 14.21, a current ratio of 14.21 and a debt-to-equity ratio of 0.01.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.04). Regenxbio had a negative return on equity of 9.90% and a negative net margin of 41.99%. The business had revenue of $0.88 million during the quarter. On average, research analysts predict that Regenxbio Inc will post -3.21 EPS for the current fiscal year.
RGNX has been the subject of several recent analyst reports. Raymond James upgraded Regenxbio from an “outperform” rating to a “strong-buy” rating and set a $94.00 price target for the company in a report on Tuesday, February 5th. BidaskClub downgraded Regenxbio from a “hold” rating to a “sell” rating in a report on Thursday, May 2nd. ValuEngine upgraded Regenxbio from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 5th. Evercore ISI upgraded Regenxbio from an “in-line” rating to an “outperform” rating and set a $51.25 price target for the company in a report on Monday, February 25th. Finally, Zacks Investment Research downgraded Regenxbio from a “buy” rating to a “hold” rating in a report on Saturday, February 23rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Regenxbio presently has a consensus rating of “Buy” and an average price target of $78.72.
Hedge funds have recently bought and sold shares of the company. Berman Capital Advisors LLC acquired a new position in shares of Regenxbio during the fourth quarter worth about $33,000. NumerixS Investment Technologies Inc acquired a new position in shares of Regenxbio during the fourth quarter worth about $50,000. Mckinley Capital Management LLC Delaware boosted its position in shares of Regenxbio by 51.8% during the first quarter. Mckinley Capital Management LLC Delaware now owns 888 shares of the biotechnology company’s stock worth $51,000 after buying an additional 303 shares during the period. Financial Gravity Wealth Inc. acquired a new position in shares of Regenxbio during the first quarter worth about $55,000. Finally, PNC Financial Services Group Inc. boosted its position in shares of Regenxbio by 568.5% during the first quarter. PNC Financial Services Group Inc. now owns 1,190 shares of the biotechnology company’s stock worth $68,000 after buying an additional 1,012 shares during the period. 84.06% of the stock is owned by institutional investors.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Story: Total Return
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.